Almost 2 billion doses of Covid-19 vaccine have been administered worldwide to date. But is it enough to wipe out Sars-CoV-2? Of course, those shots are not evenly spread across all continents. In terms of sheer numbers,
North America and Europe managed about 370 million shots each. South America with Covid-stricken countries like Brazil has a lot of catching up to do. Africa and its more than 1.3 billion people only received 34 million doses so far while Asia is storming ahead with more than 1 billion shots. But that doesn’t mean Asia is fully vaccinated. Far from it.
There are huge gaps, like in Vietnam, a country that has long been praised for its response to the pandemic. Now it is faced with new outbreaks and a new variant.
Vaccines are medicines that train the body to defend itself against future disease, and they have been saving human lives for hundreds of years. Vaccines are medicines that train the body to defend itself against future disease.
Hypertrophic cardiomyopathy is a thickening of the heart muscle, making it more difficult to pump blood. Dr. Steve Ommen is a Mayo Clinic cardiologist who specializes in the disease. He says shortness of breath or chest pain, especially during exercise, are common symptoms. Many people with the disease won’t have any significant health problems. But there are cases that require treatment. If a patient has symptoms that affect quality of life, the disease is treated with medications. Surgery or other procedures also may be necessary in some cases.
The rollout of the Johnson & Johnson vaccine has been paused in the US, Europe and South Africa after reports of rare blood clotting in a very small number of people. Health authorities said they were halting the use of the shot while they investigate the cases — and that they were doing this out of “an abundance of caution.” The Astra Zeneca jab was also recently temporarily suspended in some countries after being linked to rare blood clots. Authorities are calling it a short “pause.” The US’s Johnson and Johnson vaccine has hit the same stumbling block as the UK’s AstraZeneca jab did last month: a likely link to a rare and deadly blood clot. Use of Johnson and Johnson’s Janssen vaccine has now been halted across the US, Europe and South Africa, with health authorities investigating six incidents of clotting in younger women, one of them fatal. The US-developed vaccine uses an adenovirus to trigger immunity – the same mechanism as the UK’s AstraZeneca vaccine. It accounts for roughly 5 percent of vaccines delivered so far in the US. This is a setback to Europe, too. Johnson and Johnson announced it will delay it’s rollout on the continent. The company had already started processing an order from the EU of 200 million doses. The Janssen jab has been partially rolled out in Africa, where a majority of countries don’t have enough vaccines even for their healthcare workers. The African Union signed a deal for 220 million doses this year. But US authorities remain hopeful. They’re saying it could only be a matter of days before the rollout resumes.
Remember the first COVID-19 vaccine jabs? They gave us hope that life might return to what it was before the pandemic. If we could only get enough people vaccinated. But some of the nations leading the world in vaccinations are still struggling with the coronavirus.
An aggressive Covid-19 variant called P.1 has spread from the Amazon to other parts of Brazil and has now been identified in U.S. cases. WSJ’s Paulo Trevisani reports from Porto Alegre’s overwhelmed hospitals, where doctors say young people are getting ill. Photo: Tommaso Protti for The Wall Street Journal